Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Sanofi/Micromet, Cephalon/BioAssets, GSK/SuperGen...

Executive Summary

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

You may also be interested in...



Micromet Gets $12M Upfront From Sanofi For Discovery-Stage Oncology Antibody

This is Sanofi-Aventis' third oncology partnership this year, as it continues to seek new cancer drugs to replace Taxotere and Eloxatin.

PPD To Spin Out Compound Partnering Unit And Invest In Celtic Pharmaceutical

The CRO looks to remake itself and invest $100 million in Celtic Pharmaceutical Holdings, which wants mid-stage development projects.

Glaxo And SuperGen Team Up In An Option Deal For Cancer Targets

GlaxoSmithKline will pay $5 million upfront for an option to develop cancer drugs based on epigenetic targets; deal is GSK's sixth option-alliance this year.

Related Content

Topics

UsernamePublicRestriction

Register

PS051624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel